Paolo Ghia, MD, PhD, on Clinical Implications of Treating CLL/SLL With Ibrutinib Plus Venetoclax

Posted: Tuesday, June 22, 2021

Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, discusses the clinical significance of findings from the CAPTIVATE study, which showed that an all-oral, chemotherapy-free regimen of ibrutinib plus venetoclax may benefit patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Dr. Ghia also talks about what can be achieved in terms of treatment-free remission.